Toronto man acquitted in choking attack after cannabis-psychosis defense

Court Accepts Cannabis-Psychosis Defense in Assault Case

An Ontario court ruled that the defendant lacked the mental capacity to form criminal intent during the attack, accepting psychiatric evidence of cannabis-induced psychosis. The acquittal follows testimony from a court-appointed psychiatrist who concluded the accused "was either suffering from cannabis induced psychosis, sleepwalking or a combination of the two" at the time of the choking incident involving a young girl in Toronto.

The case represents a rare application of the automatism defense—a legal doctrine that absolves defendants who commit acts while in a state of unconsciousness or involuntary action. Under Canadian criminal law, automatism can negate criminal liability if the defendant's actions were genuinely involuntary and unpredictable.

The defendant's legal team presented psychiatric evidence linking high-THC cannabis consumption to acute psychotic episodes in susceptible individuals. No prior history of violence. The court found that the psychotic state was an unforeseeable reaction to cannabis use.

Rising Precedent for Cannabis-Psychosis Claims in Canadian Courts

The acquittal follows a 2022 Supreme Court of Canada ruling that expanded the automatism defense to include extreme intoxication, overturning a 1995 law that barred intoxication as a defense for violent crimes. That landmark decision in R. v. Brown struck down Section 33.1 of the Criminal Code, which had prohibited defendants from using self-induced intoxication as a defense in cases involving assault or interference with bodily integrity.

Since the Brown ruling, Canadian courts have seen a modest uptick in automatism defenses tied to cannabis and other substances. Successful claims remain rare. Legal experts note they require strong psychiatric evidence demonstrating that the defendant's mental state was genuinely involuntary—not merely impaired judgment.

This Toronto case adds to a small but growing body of Canadian case law exploring the psychiatric risks of high-potency THC products. Health Canada's 2025 cannabis-safety review flagged psychosis as a known adverse event in individuals with genetic predispositions or prior mental-health conditions, but stopped short of recommending product restrictions.

What This Means for Cannabis Regulation and Criminal Defense

The acquittal is likely to intensify debate over warning-label requirements and THC-potency caps in Canada's legal cannabis market. Advocacy groups have long pressed Health Canada to mandate clearer psychosis warnings on high-THC products, citing European models where Germany's BfArM requires explicit mental-health advisories on cannabis packaging above 15 percent THC.

Defense attorneys specializing in cannabis cases say the ruling could embolden similar defenses in jurisdictions with legalized cannabis, though success hinges on jurisdictional differences in automatism law. In the United States, most states don't recognize voluntary intoxication as a complete defense to violent crimes, and involuntary-intoxication claims face higher evidentiary bars than in Canada.

For operators and regulators, the case underscores the liability risks of under-warning consumers about rare but severe psychiatric reactions. Industry observers expect renewed calls for standardized mental-health screening tools at dispensaries and mandatory psychosis disclosures on high-THC edibles and concentrates.

For full background on this legal trend, see the CannIntel topic hub on cannabis-induced psychosis.

The next signal to watch: whether Health Canada revises its cannabis-labeling framework in response to mounting psychiatric case law. The agency's next regulatory review is slated for Q2 2027.